Abstract:ObjectiveTo construct a recombinant Listeria ivanovii (LI) strain that expressed Mycobacterium tuberculosis (MTB) specific antigen protein as a novel multistage tuberculosis (TB) vaccine candidate, and evaluate the biosafety and immunogenicity in mouse model.MethodsT cell epitopes of four genes related to different stages of MTB infection were fused in series to form an antigen gene, i.e. the multistage antigen gene (named msv). Then msv was inserted into the targeting plasmid that contained LI homologous sequences. Recombinant LI strain was obtained by transfecting LI with targeting plasmid and screening the recombinant LI strain that carried msv in the genome after series of homologous gene recombination processes. The growth rate of the recombinant LI strain in vitro was observed and the expression of target protein was verified by Western blot. The 50% lethal dose (LD 50) of the recombinant strain to C57BL/6 mice was measured. Mice were intravenously inoculated with vaccine candidate in dose of 0.1×LD 50.The serum alanine aminotransferase (ALT) levels, bacterial load in organs, and organ pathological sections before and 1, 2, 3, 5, 7, 14 d after vaccination were used to evaluate the safety of vaccine candidate strain. To analyze the immunogenicity of vaccine candidate strain, mice were intravenously inoculated with LI- msv, LI, and NS respectively. Nine days post immunization, the spleens were isolated under sterile conditions and splenocytes were collected and stimulated. Lyphocytes which secret specific cytokines, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2 were analyzed by flow cytometry.ResultsA recombinant strain named LI- msv which was capable of expressing the multistage TB antigen protein was successfully constructed. The LD 50 value of LI- msv for C57BL/6 mice (i.v.) was 3.3×10 8 CFU. After intravenously immunized the mice, this strain mainly multiplied in the liver and spleen, and was cleared at 7 d post innoculation. Such infection process caused transient pathological damages of the liver and spleen. Results of flow cytometry showed specific IFN-γ + CD4 + and IFN-γ + CD8 +T lymphocytes were successfully induced in LI -msv immunized mice spleen lymphocytes. The frequency of IFN-γ positive CD4 + and CD8 +T cells was significantly higher than those of vector control group and NS control group ( P<0.005). Additionally, the frequency of specific TNF-α + CD4 + T cell in LI -msv immunized group was significantly higher than that of vector control ( P<0.01) and NS control group ( P<0.005), and TNF-α + CD8 + T cell frequency obviously increased than NS control group ( P<0.005).ConclusionsA novel multistage TB vaccine candidate expressing TB multistage antigen based on LI was successfully constructed. This vaccine candidate is safe and can induce specific cellular immune response to some extent. It is promising to be further studied as a candidate vaccine against tuberculosis.

The Triplevalent DNA Vaccine for Mycobacterium Tuberculosis and Its Immunogenicity

Construction of Multivalent DNA Vaccines Formycobacterium Tuberculosis and Its Immunogenicity

Study on Immunogenicity and Protective Efficacy of Tetravalent Combination M-Tuberculosis Dna Vaccinea

[Construction and Evaluation of a Tuberculosis Multistage Vaccine Candidate Based on Recombinant Listeria Ivanovii].

[Immunogenicity and Protection of Divalent DNA Vaccine Encoding Antigens MPT83 and MPT64 of Mycobacterium Tuberculosis].

Humoral and Cellular Immune Responses Elicited by the Trivalent DNA Vaccine Against Mycobacterium Tuberculosis

Immune Responses and Protective Efficacy of the Gene Vaccine Expressing Ag85B and ESAT6 Fusion Protein Frommycobacterium Tuberculosis

Combined Recombinant DNA Vaccine Results in Significant Protection Against Mycobacterium Tuberculosis

Immune Response Induced by the Trivalent DNA Vaccine from Mycobacterium Tuberculosis in Cows

[Construction of Ag85B DNA Vaccine for Mycobacterium Tuberculosis and Its Immunogenicities].

[Construction and Immunogenicity of DNA Vaccine Encoding Secreted Form of Ag85B Protein of Mycobacterium Tuberculosis].

ESAT-6 DNA Vaccine for Mycobacterium Tuberculosis and Its Humoral and T-cell Response As Well As Its Protective Efficacy

Immunogenicity and Protective Efficacy Study Using Combination of Four Tuberculosis Dna Vaccines

Gene Vaccination of Mycobacterium Tuberculosis DNA Vaccine Encoding Mature Form of Ag85B

Construction and immunogenicity of DNA vaccine of Ag85A gene of mycobacterium tuberculosis

Ag85A DNA Vaccination Boosting Enhances BCG Primed-Mice Anti-Tuberculosis T Cell Responses

Protection of Mice with a Divalent Tuberculosis DNA Vaccine Encoding Antigens Ag85B and MPT64

Immunogenicity of DNA vaccine expressing ESAT6-CFP10 fusion protein of Mycobacterium tuberculosis

[Protective Efficacy of DNA Vaccines Encoding Mycobacterium Tuberculosis Ag85B Protein].

Immunity Characteristics Induced by a Genetic Vaccine Expressing Ag85B-ESAT6 Fusion Protein

A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice